Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Videos

Related Content

Advertisement

October 9th 2024

Blue Shield California Offers Adalimumab Biosimilar for a Quarter of Reference Price

Victoria Johnson

October 3rd 2024

Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD

October 8th 2024

FDA Issues Second CRL for Dasiglucagon (Zegalogue) in Congenital Hyperinsulinism

Patrick Campbell

September 30th 2024

The Medical Sisterhood: Confronting Imposter Syndrome, with Tina Bhutani, MD, MAS

Mona Shahriari, MD, FAAD

October 8th 2024

Pulmonology Month in Review: September 2024

Tim Smith

October 8th 2024

Time-Restricted Eating Shows Promise for Metabolic Syndrome in 3-Month Trial

Patrick Campbell

Related Content

Advertisement

October 9th 2024

Blue Shield California Offers Adalimumab Biosimilar for a Quarter of Reference Price

Victoria Johnson

October 3rd 2024

Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD

October 8th 2024

FDA Issues Second CRL for Dasiglucagon (Zegalogue) in Congenital Hyperinsulinism

Patrick Campbell

September 30th 2024

The Medical Sisterhood: Confronting Imposter Syndrome, with Tina Bhutani, MD, MAS

Mona Shahriari, MD, FAAD

October 8th 2024

Pulmonology Month in Review: September 2024

Tim Smith

October 8th 2024

Time-Restricted Eating Shows Promise for Metabolic Syndrome in 3-Month Trial

Patrick Campbell